• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Mechanisms of action for different checkpoint inhibitors.

作者信息

Berraondo Pedro

机构信息

Program of Immunology and Immunotherapy, Cima Universidad de Navarra, Pamplona, Spain.

Navarra Institute for Health Research (IDISNA), Pamplona, Spain.

出版信息

Hemasphere. 2019 Jun 30;3(Suppl). doi: 10.1097/HS9.0000000000000244. eCollection 2019 Jun.

DOI:10.1097/HS9.0000000000000244
PMID:35309798
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8925675/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/129f/8925675/c04ae67b26ef/hs9-3-0028-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/129f/8925675/c04ae67b26ef/hs9-3-0028-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/129f/8925675/c04ae67b26ef/hs9-3-0028-g001.jpg

相似文献

1
Mechanisms of action for different checkpoint inhibitors.不同检查点抑制剂的作用机制。
Hemasphere. 2019 Jun 30;3(Suppl). doi: 10.1097/HS9.0000000000000244. eCollection 2019 Jun.
2
The challenges of checkpoint inhibition in the treatment of multiple myeloma.在多发性骨髓瘤治疗中抑制检查点所面临的挑战。
Cell Immunol. 2018 Dec;334:87-98. doi: 10.1016/j.cellimm.2018.10.003. Epub 2018 Oct 13.
3
Future Strategies Involving Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.晚期尿路上皮癌中免疫检查点抑制剂的未来策略。
Curr Treat Options Oncol. 2020 Dec 2;22(1):7. doi: 10.1007/s11864-020-00799-9.
4
Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity.PD-1 和 CTLA-4 阻断治疗反应和耐药的新兴动力学途径：通过应对复杂性来解决不确定性。
J Exp Clin Cancer Res. 2021 Feb 18;40(1):74. doi: 10.1186/s13046-021-01872-3.
5
Immune checkpoint inhibitors in melanoma.黑色素瘤的免疫检查点抑制剂。
Lancet. 2021 Sep 11;398(10304):1002-1014. doi: 10.1016/S0140-6736(21)01206-X.
6
The Role of Gut Microbiota in Overcoming Resistance to Checkpoint Inhibitors in Cancer Patients: Mechanisms and Challenges.肠道微生物群在克服癌症患者对检查点抑制剂耐药中的作用：机制和挑战。
Int J Mol Sci. 2021 Jul 27;22(15):8036. doi: 10.3390/ijms22158036.
7
Immune checkpoint inhibitors side effects and management.免疫检查点抑制剂的副作用及管理
Immunotherapy. 2016 Jun;8(7):799-807. doi: 10.2217/imt-2016-0029.
8
Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy.介入治疗联合免疫检查点抑制剂：免疫治疗时代癌症治疗的新机遇。
Cancer Treat Rev. 2019 Mar;74:49-60. doi: 10.1016/j.ctrv.2018.08.006. Epub 2018 Aug 20.
9
Immunotherapy against endocrine malignancies: immune checkpoint inhibitors lead the way.免疫疗法治疗内分泌恶性肿瘤：免疫检查点抑制剂引领潮流。
Endocr Relat Cancer. 2017 Dec;24(12):T261-T281. doi: 10.1530/ERC-17-0222. Epub 2017 Sep 11.
10
Capillary-leak syndrome: an unrecognized early immune adverse effect of checkpoint-inhibitors treatment.毛细血管渗漏综合征：一种未被识别的检查点抑制剂治疗早期免疫不良反应。
Immunotherapy. 2021 Jun;13(8):653-659. doi: 10.2217/imt-2020-0332. Epub 2021 Apr 13.

引用本文的文献

1
The diversity of inhibitory receptor co-expression patterns of exhausted CD8 T cells in oropharyngeal carcinoma.口咽癌中耗竭性CD8 T细胞抑制性受体共表达模式的多样性
iScience. 2024 Apr 5;27(5):109668. doi: 10.1016/j.isci.2024.109668. eCollection 2024 May 17.
2
Contribution of tumour and immune cells to PD-L1 expression as a predictive biomarker in metastatic triple-negative breast cancer: exploratory analysis from KEYNOTE-119.肿瘤和免疫细胞对 PD-L1 表达的贡献作为转移性三阴性乳腺癌的预测生物标志物：KEYNOTE-119 的探索性分析。
J Pathol Clin Res. 2024 May;10(3):e12371. doi: 10.1002/2056-4538.12371.
3
Immunotherapy-induced Hepatotoxicity: A Review.

本文引用的文献

1
Intratumoral Tcf1PD-1CD8 T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy.具有干性特征的肿瘤内 Tcf1PD-1CD8 T 细胞促进接种疫苗和检查点阻断免疫治疗后的肿瘤控制。
Immunity. 2019 Jan 15;50(1):195-211.e10. doi: 10.1016/j.immuni.2018.12.021. Epub 2019 Jan 8.
2
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12.成功的抗 PD-1 癌症免疫疗法需要涉及细胞因子 IFN-γ 和 IL-12 的 T 细胞-树突状细胞串扰。
Immunity. 2018 Dec 18;49(6):1148-1161.e7. doi: 10.1016/j.immuni.2018.09.024. Epub 2018 Dec 11.
3
免疫疗法诱导的肝毒性：综述
J Clin Transl Hepatol. 2022 Dec 28;10(6):1194-1204. doi: 10.14218/JCTH.2022.00105. Epub 2022 Jul 22.
4
Absence of Biomarker-Driven Treatment Options in Small Cell Lung Cancer, and Selected Preclinical Candidates for Next Generation Combination Therapies.小细胞肺癌中缺乏生物标志物驱动的治疗方案以及下一代联合疗法的部分临床前候选药物
Front Pharmacol. 2021 Aug 31;12:747180. doi: 10.3389/fphar.2021.747180. eCollection 2021.
5
Current management of melanoma patients with nodal metastases.黑色素瘤患者淋巴结转移的当前治疗方法。
Clin Exp Metastasis. 2022 Feb;39(1):181-199. doi: 10.1007/s10585-021-10099-7. Epub 2021 May 7.
6
Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With Nivolumab.接受伊匹木单抗联合纳武单抗治疗的恶性黑色素瘤患者发生生殖器外硬化性苔藓的情况。
Front Oncol. 2020 Oct 7;10:573527. doi: 10.3389/fonc.2020.573527. eCollection 2020.
Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity.
肿瘤条件性抗 CTLA4 可将抗肿瘤疗效与免疫治疗相关毒性分离。
J Clin Invest. 2019 Jan 2;129(1):349-363. doi: 10.1172/JCI123391. Epub 2018 Dec 10.
4
Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors.试验观察：PD1/PDL1免疫检查点抑制剂的临床试验概况
Nat Rev Drug Discov. 2018 Nov 28;17(12):854-855. doi: 10.1038/nrd.2018.210.
5
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization.癌症免疫治疗的范式转变：从增强到正常化。
Cell. 2018 Oct 4;175(2):313-326. doi: 10.1016/j.cell.2018.09.035.
6
Epigenetic control of CD8 T cell differentiation.CD8 T 细胞分化的表观遗传控制。
Nat Rev Immunol. 2018 May;18(5):340-356. doi: 10.1038/nri.2017.146. Epub 2018 Jan 30.
7
The diverse functions of the PD1 inhibitory pathway.PD1 抑制通路的多种功能。
Nat Rev Immunol. 2018 Mar;18(3):153-167. doi: 10.1038/nri.2017.108. Epub 2017 Nov 13.
8
Confusing signals: recent progress in CTLA-4 biology.令人困惑的信号：CTLA-4生物学的最新进展
Trends Immunol. 2015 Feb;36(2):63-70. doi: 10.1016/j.it.2014.12.001. Epub 2015 Jan 9.
9
Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies.肿瘤微环境和 Fc 受体对免疫调节抗体活性的影响。
Trends Immunol. 2014 Jul;35(7):290-8. doi: 10.1016/j.it.2014.05.002. Epub 2014 Jun 18.
10
The danger model: a renewed sense of self.危险模型：对自我的全新认知。
Science. 2002 Apr 12;296(5566):301-5. doi: 10.1126/science.1071059.